Pharmacological dimerization and activation of the exchange factor eIF2B antagonizes the integrated stress response

  1. Carmela Sidrauski  Is a corresponding author
  2. Jordan C Tsai
  3. Martin Kampmann
  4. Brian R Hearn
  5. Punitha Vedantham
  6. Priyadarshini Jaishankar
  7. Masaaki Sokabe
  8. Aaron S Mendez
  9. Billy W Newton
  10. Edward L Tang
  11. Erik Verschueren
  12. Jeffrey R Johnson
  13. Nevan J Krogan
  14. Christopher S Fraser
  15. Jonathan S Weissman
  16. Adam R Renslo
  17. Peter Walter
  1. University of California, San Francisco, United States
  2. Howard Hughes Medical Institution, University of California, San Francisco, United States
  3. University of California, Davis, United States

Abstract

The general translation initiation factor eIF2 is a major translational control point. Multiple signaling pathways in the integrated stress response phosphorylate eIF2 serine-51, inhibiting nucleotide exchange by eIF2B. ISRIB, a potent drug-like small molecule, renders cells insensitive to eIF2α phosphorylation and enhances cognitive function in rodents by blocking long-term depression. ISRIB was identified in a phenotypic cell-based screen, and its mechanism of action remained unknown. We now report that ISRIB is an activator of eIF2B. Our reporter-based shRNA screen revealed an eIF2B requirement for ISRIB activity. Our results define ISRIB as a symmetric molecule, show ISRIB-mediated stabilization of activated eIF2B dimers, and suggest that eIF2B4 (δ-subunit) contributes to the ISRIB binding site. We also developed new ISRIB analogs, improving its EC50 to 600 pM in cell culture. By modulating eIF2B function, ISRIB promises to be an invaluable tool in proof-of-principle studies aiming to ameliorate cognitive defects resulting from neurodegenerative diseases.

Article and author information

Author details

  1. Carmela Sidrauski

    Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States
    For correspondence
    carmelas@me.com
    Competing interests
    CS: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.
  2. Jordan C Tsai

    Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5202-722X
  3. Martin Kampmann

    Howard Hughes Medical Institution, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3819-7019
  4. Brian R Hearn

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    BRH: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.
  5. Punitha Vedantham

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    PV: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.
  6. Priyadarshini Jaishankar

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  7. Masaaki Sokabe

    Department of Molecular and Cellular Biology, College of Biological Sciences, University of California, Davis, Davis, United States
    Competing interests
    No competing interests declared.
  8. Aaron S Mendez

    Howard Hughes Medical Institution, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  9. Billy W Newton

    QB3, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  10. Edward L Tang

    QB3, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  11. Erik Verschueren

    QB3, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5842-6344
  12. Jeffrey R Johnson

    QB3, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  13. Nevan J Krogan

    QB3, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  14. Christopher S Fraser

    Department of Molecular and Cellular Biology, College of Biological Sciences, University of California, Davis, Davis, United States
    Competing interests
    No competing interests declared.
  15. Jonathan S Weissman

    Howard Hughes Medical Institution, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  16. Adam R Renslo

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    ARR: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.
  17. Peter Walter

    Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States
    Competing interests
    PW: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.

Funding

Howard Hughes Medical Institute (HHMI)

  • Carmela Sidrauski
  • Jordan C Tsai
  • Martin Kampmann
  • Aaron S Mendez
  • Jonathan S Weissman
  • Peter Walter

The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2015, Sidrauski et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 9,122
    views
  • 2,079
    downloads
  • 213
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Carmela Sidrauski
  2. Jordan C Tsai
  3. Martin Kampmann
  4. Brian R Hearn
  5. Punitha Vedantham
  6. Priyadarshini Jaishankar
  7. Masaaki Sokabe
  8. Aaron S Mendez
  9. Billy W Newton
  10. Edward L Tang
  11. Erik Verschueren
  12. Jeffrey R Johnson
  13. Nevan J Krogan
  14. Christopher S Fraser
  15. Jonathan S Weissman
  16. Adam R Renslo
  17. Peter Walter
(2015)
Pharmacological dimerization and activation of the exchange factor eIF2B antagonizes the integrated stress response
eLife 4:e07314.
https://doi.org/10.7554/eLife.07314

Share this article

https://doi.org/10.7554/eLife.07314

Further reading

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics
    Federico A Vignale, Andrea Hernandez Garcia ... Adrian G Turjanski
    Research Article

    Yerba mate (YM, Ilex paraguariensis) is an economically important crop marketed for the elaboration of mate, the third-most widely consumed caffeine-containing infusion worldwide. Here, we report the first genome assembly of this species, which has a total length of 1.06 Gb and contains 53,390 protein-coding genes. Comparative analyses revealed that the large YM genome size is partly due to a whole-genome duplication (Ip-α) during the early evolutionary history of Ilex, in addition to the hexaploidization event (γ) shared by core eudicots. Characterization of the genome allowed us to clone the genes encoding methyltransferase enzymes that catalyse multiple reactions required for caffeine production. To our surprise, this species has converged upon a different biochemical pathway compared to that of coffee and tea. In order to gain insight into the structural basis for the convergent enzyme activities, we obtained a crystal structure for the terminal enzyme in the pathway that forms caffeine. The structure reveals that convergent solutions have evolved for substrate positioning because different amino acid residues facilitate a different substrate orientation such that efficient methylation occurs in the independently evolved enzymes in YM and coffee. While our results show phylogenomic constraint limits the genes coopted for convergence of caffeine biosynthesis, the X-ray diffraction data suggest structural constraints are minimal for the convergent evolution of individual reactions.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Angel D'Oliviera, Xuhang Dai ... Jeffrey S Mugridge
    Research Article

    The SARS-CoV-2 main protease (Mpro or Nsp5) is critical for production of viral proteins during infection and, like many viral proteases, also targets host proteins to subvert their cellular functions. Here, we show that the human tRNA methyltransferase TRMT1 is recognized and cleaved by SARS-CoV-2 Mpro. TRMT1 installs the N2,N2-dimethylguanosine (m2,2G) modification on mammalian tRNAs, which promotes cellular protein synthesis and redox homeostasis. We find that Mpro can cleave endogenous TRMT1 in human cell lysate, resulting in removal of the TRMT1 zinc finger domain. Evolutionary analysis shows the TRMT1 cleavage site is highly conserved in mammals, except in Muroidea, where TRMT1 is likely resistant to cleavage. TRMT1 proteolysis results in reduced tRNA binding and elimination of tRNA methyltransferase activity. We also determined the structure of an Mpro-TRMT1 peptide complex that shows how TRMT1 engages the Mpro active site in an uncommon substrate binding conformation. Finally, enzymology and molecular dynamics simulations indicate that kinetic discrimination occurs during a later step of Mpro-mediated proteolysis following substrate binding. Together, these data provide new insights into substrate recognition by SARS-CoV-2 Mpro that could help guide future antiviral therapeutic development and show how proteolysis of TRMT1 during SARS-CoV-2 infection impairs both TRMT1 tRNA binding and tRNA modification activity to disrupt host translation and potentially impact COVID-19 pathogenesis or phenotypes.